Pyrvinium Pamoate

扑蛲灵

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NamePyrvinium Pamoate
Drug Alias NameViprynium Pamoate扑蛲喹恩波维胺恩波吡维铵恩波酸吡维铵 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionWnt signalling pathway inhibitors
TargetsNot applicable
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsCarcinoma, Pancreatic Ductal +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1956/01/01
Country/TerritoryUnited StatesSingaporeTaiwan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesNational University Cancer Institute, SingaporeVanderbilt University Medical CenterThomas Jefferson University
Inactive CompaniesParke Davis Pharmaceutical Research Div Warner Lambert Co
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsEnterobiasisHelminthiasis

Other Information

ATC CodeP02CX01
Related LinksWikipediaDrugBankKEGG